Lyka Labs Ltd

LYKALABS
NSE· Healthcare
₹72.33
-2.50 (-3.34%)
Updated 12:15 pm IST
52W Low · ₹45.8052W High · ₹121.44
Mid Range
Market Cap
₹226.88L Cr
Volume
20.8K
Prev Close
₹68.58
ISIN
INE933A01014

Orion Score

Fundamentals-based quality & risk · not a recommendation

33/100
Avoid

Lyka Labs Ltd scores 33/100 (Avoid) on the Orion Score — weak business quality (37), poor growth (17), poor balance-sheet safety (26) and fair valuation (51). A fundamentals-based quality & risk score, not a buy/sell recommendation.

Quality
37
Growth
17
Safety
26
Value
51

Full Orion analysis

Risk checks

  • Profit converts to cash (CFO 4.8× PAT)
  • Low debt, comfortable interest cover
  • No distress, manipulation or dilution flags

Forensic accounting

Piotroski F 3/9Altman Z Safe(4.46)Beneish M Clean(-3.14)

Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check

Technical / Momentum

Price Trend

45/100

Neutral

Technical momentum companion — separate from the fundamentals-based Orion Score.

Unlock with Pro

Upgrade →

VestAI Stock Score

VALUATION
Low Debt
D/E 0.31x — lean balance sheet
QUALITY
Low Quality
ROCE -10.0% — poor capital efficiency
MOMENTUM
Bullish
RSI 64.8 — strong momentum

Price Chart

SMA 20
SMA 50
SMA 200

Key Fundamentals

Q4 FY2026

P/E Ratio
—
ROCE
-10.04%
ROE (1Y)
9.31%
D/E Ratio
0.31x
OPM
-30.31%
TTM EPS
₹-2.81
Dividend Yield
0.00%
Qtrly Sales
₹28.03 Cr
Qtrly Profit
₹-7.61 Cr

Technical Signals

Quarterly Results

Revenue & Profit in ₹ Crores

Revenue Net Profit
QuarterRevenueNet ProfitOPMEPS
Q4 2026₹28.03₹-7.61-30.3%₹-2.13
Q3 2026₹30.73₹0-1.7%₹0.00
Q2 2026₹36.66₹-3.36-12.8%₹-0.94
Q1 2026₹33.03₹0.934.8%₹0.25
Q4 2025₹33.43₹1.778.0%₹0.49

Annual P&L

Revenue & Profit in ₹ Crores (Yearly)

Revenue Net Profit
YearRevenueNet ProfitEBITDAOPM
FY 2026₹128.44₹-10.03₹-0.16-9.4%
FY 2025₹138.5₹8.01₹20.178.1%
FY 2024₹105.13₹-2.49₹16.562.8%
FY 2023₹88.34₹-13.21₹12.73.1%

Peer Comparison — Healthcare

Top companies in the same sector by market cap

CompanyMkt CapP/EROCEROED/EOPM
LYKALABS ★₹227 Cr—-10.04%9.31%0.31x-30.31%
SUNPHARMA₹4,27,609 Cr37.3215.73%14.72%0.06x18.90%
MAXHEALTH₹95,110 Cr66.2111.94%14.33%0.32x22.56%
AUROPHARMA₹90,029 Cr25.9412.55%9.93%0.21x15.11%
ABBOTINDIA₹57,724 Cr36.6336.14%34.46%0.04x27.01%
AJANTPHARM₹41,836 Cr39.5527.99%25.39%0.06x51.40%

Balance Sheet

All values in ₹ Crores

MetricFY 2025FY 2024FY 2023FY 2022
Total Assets₹176.21₹156.86₹151.52₹185.61
Equity₹103.55₹68.15₹45.44₹13.34
Total Debt₹38.17₹57.7₹73.68₹129.24
Cash₹0.39₹0.26₹2.74₹1.35
Net Debt₹36.52₹55.36₹67.35₹126.39
Working Capital₹20.8₹12.88₹11.61₹-47.15

Shareholding Pattern

Q1 FY2027

Promoter
59.94%
FII
0%
DII
0%
Public
40.06%

Quarter-over-Quarter Trend

QuarterPromoterFIIDIIPublic
Q1 FY202759.94% ↑0% ↓0% ↓40.06% ↓
Q3 FY202658.16%0.17%0.66%40.99%
Q2 FY202658.16%0.17% ↑0.66%40.99% ↓
Q1 FY202658.16%0.16% ↓0.66%41.02% ↑
Q4 FY202558.16% ↑0.24% ↑0.66%40.93% ↓
Q3 FY202558.11%0.15%0.66%41.07%
Q2 FY202558.11%0.15%0.66% ↓41.08% ↑
Q1 FY202558.11%0.15%0.75%40.99%

Corporate Actions

No recent corporate actions

Analyse LYKALABS with Orion AI

Ask: "Is Lyka Labs Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation

Analyse with Orion

Want more insights like this?

Get free stock analysis, market insights, and investment ideas delivered to your inbox.

No spam. Unsubscribe anytime.

About Lyka Labs Ltd (LYKALABS) Stock

Lyka Labs Ltd is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE933A01014. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.